ClinicalTrials.gg
CompletedNCT06999902POWER1Updated Aug 10, 2026

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

A Phase 2/3 interventional study of 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks and Placebo in Focal Seizure, sponsored by Praxis Precision Medicines. Completed at 69 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Praxis Precision Medicines · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Enrollment
49th of 306
255 · median 56
Started
2024
with 19 others
Phase 2/3
10 of 395
none open now
Registered
365th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 49th largest by enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2024, is one of 10 in phase 2/3, and was the 365th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)

Read the detailed description

PRAX-628-321 (POWER1) is a double-blind, randomized, multicenter, trial to evaluate the efficacy and safety of PRAX-628 in adults who can attest to concurrently taking at least 1, but no more than 3 acceptable anti-seizure medications.

03

Conditions studied

  • Focal Seizure

Browse trials for

Keywords

  • Focal Seizure
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of focal onset epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy.
  2. Past evidence by computed tomography (CT) or magnetic resonance imaging (MRI) that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor.

Exclusion criteria

Exclusion Criteria:

  1. Subject has had any of the of the following within the 12-month period preceding trial entry: History of pseudo or psychogenic seizures, cluster seizures where the individual seizures cannot be counted, an episode of convulsive status epilepticus requiring hospitalization and intubation, or subject only has focal seizures with awareness that do not have motor activity.
  2. Planned epilepsy surgery during the course of the clinical trial.
  3. History of neurosurgery for seizures \<1 year prior to enrollment, or radiosurgery \<2 years prior to enrollment or vagus nerve stimulation (VNS) implantation.
  4. History of schizophrenia, obsessive-compulsive disorder, or other serious mental health disorders.
  5. History of , myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.
  6. History of cardiac disease(s)/cardiac conduction disorders/or cardiac structural abnormality(ies).
  7. Has a positive test result or a known history of a positive test result for (HIV), surface antigen (HBsAg), or anti- virus (HCV) antibody at Screening.
  8. Is pregnant or is breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.
  9. Has received any other experimental or drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Randomized, Double-Blind 20mg/day for 6 weeks then 30mg/day for remaining 6 weeks PRAX-628

    Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive 20 mg of PRAX-628 for 6 weeks followed by 30 mg PRAX 628 for the remaining 6 weeks.

    Drug: 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

  • Experimental
    Randomized, Double-Blind Placebo

    Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive a matching placebo throughout the 12-week Treatment Period

    Drug: Placebo

Interventions

  • Drug20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Once daily oral

  • DrugPlacebo

    Once daily oral

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of PRAX-628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs

    Median percent change in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628 compared to placebo.

    Time frame: 12 weeks

Secondary outcomes

  1. To evaluate the efficacy of PRAX 628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs

    Proportion of participants experiencing a ≥50% reduction in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period (Responder Rate) for PRAX 628 compared to placebo.

    Time frame: 12 weeks

  2. To assess trends over time in efficacy of PRAX 628 on focal seizure frequency

    Percent change in monthly focal seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628 compared with placebo.

    Time frame: 12 weeks

  3. To evaluate the efficacy of PRAX 628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs

    Number of days post-randomization to reach the same number of monthly focal seizures as the Screening/Observation Period through the end of the Treatment Period Proportion of participants experiencing seizure freedom, 100% reduction in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628 compared with placebo Impact of PRAX-628 compared to placebo on PGI-S and CGI-S

    Time frame: 12 weeks

  4. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Incidence and severity of TEAEs, including discontinuation of study drug due to TEAEs

    Time frame: 12 weeks

  5. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Change in tympanic temperature in Celsius

    Time frame: 12 weeks

  6. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Change in heart rate in beats per minute

    Time frame: 12 weeks

  7. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Change in blood pressure in mm/Hg

    Time frame: 12 weeks

  8. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Change in respiratory rate in breaths per minute

    Time frame: 12 weeks

  9. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    The principal investigator (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events.

    Time frame: 12 weeks

  10. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Incidence of clinically significant ECG abnormalities

    Time frame: 12 weeks

  11. To assess the safety and tolerability of PRAX-628 in adults with focal seizures

    Changes in suicidality, as assessed by C-SSRS

    Time frame: 12 weeks

07

Study locations

69 sites
  • Praxis Research Site
    Phoenix, Arizona 85032, United States
  • Praxis Research Site
    Loma Linda, California 92345, United States
  • Praxis Research Site
    DeLand, Florida 32720, United States
  • Praxis Research Site
    Miami, Florida 33133, United States
  • Praxis Research Site
    Miami Lakes, Florida 33016, United States
  • Praxis Research Site
    Naples, Florida 34116, United States
  • Praxis Research Site
    Orlando, Florida 32825, United States
  • Praxis Research Site
    Chicago, Illinois 60640, United States
  • Praxis Research Site
    Lafayette, Louisiana 70508, United States
  • Praxis Research Site
    Bethesda, Maryland 20817, United States
  • Praxis Research Site
    Boston, Massachusetts 02131, United States
  • Praxis Research Site
    Plymouth, Michigan 48170, United States
  • Praxis Research Site
    Chesterfield, Missouri 63005, United States
  • Praxis Research Site
    Ozark, Missouri 65721, United States
  • Praxis Research Site
    Hackensack, New Jersey 07601, United States
  • Praxis Research Site
    Amherst, New York 14226, United States
  • Praxis Research Site
    Middletown, New York 10940, United States
  • Praxis Research Site
    New York, New York 10016, United States
  • Praxis Research Site
    Charlotte, North Carolina 28211, United States
  • Praxis Research Site
    Canton, Ohio 44718, United States
  • Praxis Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Praxis Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Praxis Research Site
    Sioux Falls, South Dakota 57105, United States
  • Praxis Research Site
    Memphis, Tennessee 38104, United States
  • Praxis Research Site
    Dallas, Texas 75206, United States
  • Praxis Research Site
    El Paso, Texas 79912, United States
  • Praxis Research Site
    Frisco, Texas 75034, United States
  • Praxis Research Site
    Round Rock, Texas 78681, United States
  • Praxis Research Site
    Seabrook, Texas 77586, United States
  • Praxis Research Site
    Waxahachie, Texas 75165, United States
  • Praxis Research Site
    Virginia Beach, Virginia 23456, United States
  • Praxis Research Site
    Campo Comprido, Curitiba PR, Brazil
  • Praxis Research Site
    Belo Horizonte, Minas Gerais, Brazil
  • Praxis Research Site
    Recife, Pernambuco, Brazil
  • Praxis Research Site
    Rio de Janeiro, Rio de Janeiro, Brazil
  • Praxis Research Site
    Porto Alegre, Rio Grande do Sul, Brazil
  • Praxis Research Site
    Botucatu, São Paulo, Brazil
  • Praxis Research Site
    Campinas, São Paulo, Brazil
  • Praxis Research Site
    Ribeirão Preto, São Paulo, Brazil
  • Praxis Research Site
    São José do Rio Preto, São Paulo, Brazil
  • Praxis Research Site
    São Paulo, São Paulo, Brazil
  • Praxis Research Site
    Surrey, British Columbia, Canada
  • Praxis Research Site
    Toronto, Ontario, Canada
  • Praxis Research Site
    Bologna, Italy
  • Praxis Research Site
    Lecco, Italy
  • Praxis Research Site
    Milan, Italy
  • Praxis Research Site
    Monserrato, Italy
  • Praxis Research Site
    Naples, Italy
  • Praxis Research Site
    Pavia, Italy
  • Praxis Research Site
    Pisa, Italy
  • Praxis Research Site
    Ponderano, Italy
  • Praxis Research Site
    Pozzilli, Italy
  • Praxis Research Site
    Roma, Italy
  • Praxis Research Site
    San Lucas Tepetlacalco, Mexico
  • Praxis Research Site
    Bydgoszcz, Poland
  • Praxis Research Site
    Katowice, Poland
  • Praxis Research Site
    Lublin, Poland
  • Praxis Research Site
    Warsaw, Poland
  • Praxis Research Site
    Valladolid, Valladolid, Spain
  • Praxis Research Site
    Barcelona, 08003, Spain
  • Praxis Research Site
    Barcelona, 08035, Spain
  • Praxis Research Site
    Barcelona, 08041, Spain
  • Praxis Research Site
    Granda, 18012, Spain
  • Praxis Research Site
    Madrid, 28006, Spain
  • Praxis Research Site
    Madrid, 28010, Spain
  • Praxis Research Site
    Madrid, 28040, Spain
  • Praxis Research Site
    Málaga, 29010, Spain
  • Praxis Research Site
    Terrassa, 08222, Spain
  • Praxis Research Site
    Valencia, 46026, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in May 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
May 31, 2025
StartActual
Dec 11, 2024
Primary completionActual
May 14, 2026
CompletionActual
May 14, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06999902
Lead sponsor
Praxis Precision Medicines
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Dec 11, 2024
Primary completion
May 14, 2026
Completion
May 14, 2026
Last update
Aug 10, 2026

Study contacts

Medical Director
study director · Praxis Precision Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion